Developed under the direction and sponsorship of Actelion Pharmaceuticals US, Inc.
a communication from WebMD Professional
Developed under the direction and sponsorship of Actelion Pharmaceuticals US, Inc.
Please see full Prescribing Information, including BOXED WARNING.
In the treatment of pulmonary arterial hypertension(PAH, WHO Group Ⅰ)Opsumit(R) macitentan tablets 10mg
Actelion remains committed to access and financial assistance for patients prescribed OPSUMIT® (macitentan)
Pay no more than $5* for Actelion oral PAH Therapy
For eligible commercially insured patients: Actelion Oral PAH Therapy Co-Pay Program*
Savings program for eligible commercially insured patients to pay $5 per fill. Contact an Actelion Pathways® Case Manager for more information. Program valid for up to $20,000 maximum program benefit per calendar year or 13 fills, whichever comes first
Free 30-day supply
Open to all eligible patients, regardless of coverage: OPSUMIT Voucher Program (OVP)
Eligible patients age 18 or older may be able to obtain a 30-day supply of OPSUMIT at no charge by requesting it from the Actelion Pathways Case Manager during enrollment. The offer is only valid for the first 30-day supply of OPSUMIT. There is no guarantee of continuous accessibility after the trial period ends
Actelion Pathways(R) Guidance. Support. Services.
Actelion Pathways is a centralized platform for information about Actelion therapies that:
Answers patient questions about their prescribed Actelion treatments
Provides assistance to patients in getting started on a new Actelion treatment
Shares information about how to help pay for treatment
Provides information about specialty pharmacies and medicine delivery
97% covered lives1†‡
OPSUMIT is covered for Commercial and Medicare Part D Patients:
97% covered lives nationally as of February 2020‡§
97.3% as of February 2020 in the US for all Commercial and Medicare Part D lives.
Collected on February 2020, and subject to change. This percentage may not represent 100% of formulary lives due to data limitations.
Reference: 1. Managed Markets Insight and Technology, LLC™, a trademark of MMIT, as of February 2020.
Call 1-866-ACTELION (1-866-228-3546) Actelion Case Managers or Therapy Access Managers can provide your office with more details about these programs
OPSUMIT is an endothelin receptor antagonist (ERA) indicated for the treatment of pulmonary arterial hypertension (PAH, WHO Group I) to reduce the risks of disease progression and hospitalization for PAH.
Effectiveness was established in a long-term study in PAH patients with predominantly WHO Functional Class II-III symptoms treated for an average of 2 years. Patients had idiopathic and heritable PAH (57%), PAH caused by connective tissue disorders (31%), and PAH caused by congenital heart disease with repaired shunts (8%).
Do not administer OPSUMIT to a pregnant female because it may cause fetal harm.
Females of reproductive potential: Exclude pregnancy before the start of treatment, monthly during treatment, and 1 month after stopping treatment. Prevent pregnancy during treatment and for one month after stopping treatment by using acceptable methods of contraception.
For all female patients, OPSUMIT is available only through a restricted program called the OPSUMIT Risk Evaluation and Mitigation Strategy (REMS).
Pregnancy: OPSUMIT may cause fetal harm when administered to a pregnant woman. OPSUMIT is contraindicated in females who are pregnant. If OPSUMIT is used during pregnancy, advise the patient of the potential risk to a fetus.
Embryo-fetal Toxicity and OPSUMIT REMS Program
Due to the risk of embryo-fetal toxicity, OPSUMIT is available for females only through a restricted program called the OPSUMIT REMS Program. For females of reproductive potential, exclude pregnancy prior to initiation of therapy, ensure use of acceptable contraceptive methods, and obtain monthly pregnancy tests.
Notable requirements of the OPSUMIT REMS Program include:
Prescribers must be certified with the program by enrolling and completing training.
All females, regardless of reproductive potential, must enroll in the OPSUMIT REMS Program prior to initiating OPSUMIT. Male patients are not enrolled in the REMS.
Females of reproductive potential must comply with the pregnancy testing and contraception requirements.
Pharmacies must be certified with the program and must only dispense to patients who are authorized to receive OPSUMIT.
ERAs have caused elevations of aminotransferases, hepatotoxicity, and liver failure. The incidence of elevated aminotransferases in the SERAPHIN study >3 x ULN was 3.4% for OPSUMIT vs 4.5% for placebo, and >8 x ULN was 2.1% vs 0.4%, respectively. Discontinuations for hepatic adverse events were 3.3% for OPSUMIT vs 1.6% for placebo.
Obtain liver enzyme tests prior to initiation of OPSUMIT and repeat during treatment as clinically indicated.
Advise patients to report symptoms suggesting hepatic injury (nausea, vomiting, right upper quadrant pain, fatigue, anorexia, jaundice, dark urine, fever, or itching).
If clinically relevant aminotransferase elevations occur, or if elevations are accompanied by an increase in bilirubin >2 x ULN, or by clinical symptoms of hepatotoxicity, discontinue OPSUMIT. Consider re-initiation of OPSUMIT when hepatic enzyme levels normalize in patients who have not experienced clinical symptoms of hepatotoxicity.
Fluid Retention
Peripheral edema and fluid retention are known consequences of PAH and ERAs. In the pivotal PAH study SERAPHIN, edema was reported in 21.9% of the OPSUMIT group vs 20.5% for placebo.
Patients with underlying left ventricular dysfunction may be at particular risk for developing significant fluid retention after initiation of ERA treatment. In a small study of pulmonary hypertension due to left ventricular dysfunction, more patients in the OPSUMIT group developed significant fluid retention and had more hospitalizations due to worsening heart failure compared to placebo. Postmarketing cases of edema and fluid retention occurring within weeks of starting OPSUMIT, some requiring intervention with a diuretic or hospitalization for decompensated heart failure, have been reported.
Monitor for signs of fluid retention after OPSUMIT initiation. If clinically significant fluid retention develops, evaluate the patient to determine the cause and the possible need to discontinue OPSUMIT.
Hemoglobin Decrease
Decreases in hemoglobin concentration and hematocrit have occurred following administration of other ERAs and in clinical studies with OPSUMIT. These decreases occurred early and stabilized thereafter.
In the SERAPHIN study, OPSUMIT caused a mean decrease in hemoglobin (from baseline to 18 months) of about 1.0 g/dL vs no change in the placebo group. A decrease in hemoglobin to below 10.0 g/dL was reported in 8.7% of the OPSUMIT group vs 3.4% for placebo. Decreases in hemoglobin seldom require transfusion.
Initiation of OPSUMIT is not recommended in patients with severe anemia. Measure hemoglobin prior to initiation of treatment and repeat during treatment as clinically indicated.
Pulmonary Edema with Pulmonary Veno-occlusive Disease (PVOD)
Should signs of pulmonary edema occur, consider the possibility of associated PVOD. If confirmed, discontinue OPSUMIT.
Decreased Sperm Counts
OPSUMIT, like other ERAs, may have an adverse effect on spermatogenesis. Counsel men about potential effects on fertility.
Most common adverse reactions (more frequent than placebo by ≥3%) were anemia (13% vs 3%), nasopharyngitis/pharyngitis (20% vs 13%), bronchitis (12% vs 6%), headache (14% vs 9%), influenza (6% vs 2%), and urinary tract infection (9% vs 6%).
Strong inducers of CYP3A4 such as rifampin significantly reduce macitentan exposure. Concomitant use of OPSUMIT with strong CYP3A4 inducers should be avoided.
Strong inhibitors of CYP3A4 like ketoconazole approximately double macitentan exposure. Many HIV drugs like ritonavir are strong inhibitors of CYP3A4. Avoid concomitant use of OPSUMIT with strong CYP3A4 inhibitors. Use other PAH treatment options when strong CYP3A4 inhibitors are needed as part of HIV treatment.
Please click here for full Prescribing Information, including BOXED WARNING.
Applies to patients who have provided consent to services offered by Actelion Pathways. The Actelion Oral PAH Therapy Co-Pay Program is only available for residents of the US and Puerto Rico who are 18 or older and have commercial health insurance with co-pay/co-insurance exceeding $5 per prescription fill per product. Patients ineligible for the Actelion Oral PAH Therapy Co-Pay Program include those enrolled in Medicare, Medicaid, VA/DoD (Tricare), the Indian Health Service, or any other federal- or state-funded healthcare program, or where prohibited by law. The Actelion Oral PAH Therapy Co-Pay Program is not prescription drug coverage or insurance. Actelion reserves the right to terminate or modify this program at any time or without notice. Other terms and conditions apply.
The voucher is only effective for the first 30-day supply of OPSUMIT and must be redeemed at the time of enrollment. This offer may not be combined with any other rebate/coupon, free trial, prescription savings card, or other similar offer. No prior or future purchase is necessary. This offer is not conditional on any past, present, or future purchase, including refills of OPSUMIT or any other product.
WHO=World Health Organization.
OPSUMIT and Actelion Pathways are registered trademarks of Actelion Pharmaceuticals Ltd
©2020 Actelion Pharmaceuticals US, Inc.  All rights reserved.  cp-154832 0620
Actelion Pharmaceuticals US, Inc.
5000 Shoreline Court, Suite 200
South San Francisco, CA 94080
Unsubscribe from WebMD Professional Clinical Update
Unsubscribe from all WebMD Professional emails
WebMD Professional Services
825 Eighth Avenue
New York, NY 10019
This promotional communication is provided by WebMD Professional Services system footer